President Donald Trump’s nominee to lead HHS, Robert F. Kennedy Jr., does not support using march-in rights under the Bayh-Dole Act to lower drug prices, he confirmed in a written response to additional questions from senators published Friday (Jan. 31). Kennedy rejected the draft framework for use of march-in rights to lower drug prices that the Biden administration had published but never finalized. “Do you believe that a drug’s price is an appropriate factor to consider in determining if the...